Pfizer

liver
Biotech

Madrigal pays Pfizer $50M for MASH drug with combo potential

Madrigal paid $50 million for a DGAT2i inhibitor that the biopharma intends to combine with its approved liver disease drug Rezdiffra.
James Waldron Jan 9, 2026 10:50am
Old vintage retro golden compass on ancient map

Pfizer maps out $865M Cartography discovery deal

Jan 6, 2026 7:30am
Alps parachute rainbow mountains

Pfizer RNA leader runs to Replicate—Chutes & Ladders

Dec 19, 2025 8:30am
helicopter rescue mission save aircraft

Athira inks deal to power ex-Pfizer asset toward phase 3 data

Dec 18, 2025 10:56am
Hundred dollar bills wrapped with a red bow under a Christmas tree

Pfizer, Sanofi round out '25 with separate autoimmune deals

Dec 15, 2025 11:06am
finance numbers tape money

Pfizer signs $1.9B pact for Fosun unit's GLP-1 drug

Dec 9, 2025 8:00am